InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
2
T+90 hit rate
25%
T+90 mean return
-3.7%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Kirchgraber Paul R, Chairman & CEO. Director active across 1 company, notably Laboratory CORP of America Holdings. Aggregated, 17 filings have been logged. Breakdown: 0 buy · 2 sells. Total volume traded: €1.1m. History available since 6 May 2021. The latest transaction was disclosed on 19 May 2023 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations17 total
◇
4,300 shares@ US$182.5130.5% of flowCommon StockSEC:0001127602-23-016525:0
6,763 shares0Common StockSEC:0001127602-23-011750:0
◇
3,000 shares@ US$182.5121.5% of flowCommon StockSEC:0001127602-23-006642:0
483 sharesCommon StockSEC:0001127602-23-005103:0
560 sharesCommon StockSEC:0001127602-23-003703:0
443 sharesCommon StockSEC:0001127602-23-003532:0
2,007 sharesCommon StockSEC:0001127602-22-024921:0
3,707 shares0Common StockSEC:0001127602-22-010503:0
317 sharesCommon StockSEC:0001127602-22-005027:0
560 sharesCommon StockSEC:0001127602-22-003649:0
560 sharesCommon StockSEC:0001127602-22-003649
443 sharesCommon StockSEC:0001127602-22-003279:0
443 sharesCommon StockSEC:0001127602-22-003279
2,007 sharesCommon StockSEC:0001127602-21-028237:0
2,007 sharesCommon StockSEC:0001127602-21-028237
▼
2,500 shares@ US$276.550.0028% mcap50.0% of flowCommon StockSEC:0001127602-21-015959:0
▼
2,500 shares@ US$276.5550.0% of flowCommon StockSEC:0001127602-21-015959
17 of 17 declarations
About Kirchgraber Paul R
Paul R. Kirchgraber is the Chief Executive Officer of Covance Drug Development at Laboratory Corp of America Holdings. He leads operations with a focus on innovation and service improvement. Kirchgraber is recognized for his leadership in the life sciences sector.
